Literature DB >> 29708525

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma.

Alessandro De Vita1, Laura Mercatali2, Giacomo Miserocchi2, Chiara Liverani2, Chiara Spadazzi2, Federica Recine2, Alberto Bongiovanni2, Federica Pieri3, Davide Cavaliere4, Valentina Fausti2, Dino Amadori2, Toni Ibrahim2.   

Abstract

Soft tissue sarcomas (STS) represent a spectrum of heterogeneous malignancies with a difficult diagnosis, classification, and management. To date, more than 50 histological subtypes of these rare solid tumors have been identified. Thus, due to their extraordinary diversity and low incidence, our understanding of the biology of these tumors is still limited. Patient-derived cultures represent the ideal platform to study STS pathophysiology and pharmacology. We thus developed a human preclinical model of STS starting from tumor specimens harvested from patients undergoing surgical resection. Patient-derived STS cell cultures were obtained from the surgical specimens by collagenase digestion and isolated by filtration. Cells were counted, seeded, and left for 14 days in standard monolayer cultures and then processed by downstream analysis. Before performing molecular or pharmaceutical analyses, the establishment of STS primary cultures was confirmed through the evaluation of cytomorphologic features and, when available, immunohistochemical markers. This method represents a useful tool 1) to study the natural history of these poorly explored malignancies and 2) to test the effects of different drugs in an effort to learn more about their mechanisms of action.

Entities:  

Mesh:

Year:  2018        PMID: 29708525      PMCID: PMC5933451          DOI: 10.3791/56767

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  27 in total

Review 1.  Current status of publicly available sarcoma cell lines for use in proteomic studies.

Authors:  Xiaoqing Pan; Akihiko Yoshida; Akira Kawai; Tadashi Kondo
Journal:  Expert Rev Proteomics       Date:  2016-01-11       Impact factor: 3.940

2.  Establishment of human tumor xenografts in immunodeficient mice.

Authors:  Christopher L Morton; Peter J Houghton
Journal:  Nat Protoc       Date:  2007       Impact factor: 13.491

3.  Bisphenol A Inhibits Cell Proliferation and Reduces the Motile Potential of Murine LM8 Osteosarcoma Cells.

Authors:  Teruki Kidani; Rie Yasuda; Joji Miyawaki; Yusuke Oshima; Hiromasa Miura; Hiroshi Masuno
Journal:  Anticancer Res       Date:  2017-04       Impact factor: 2.480

4.  Effect of vegf gene knockdown on growth of the murine sarcoma cell line MS-K.

Authors:  Xiu Y Zhong; Asami Yoshioka; Yuka Mashio; Toru Ikeda; Huijie Jiang; Maki Touma; Qiong Wu; ChangLiu Wang; Kenkichi Sugimoto
Journal:  Genes Cells       Date:  2011-04-18       Impact factor: 1.891

5.  Establishment of a primary human sarcoma model in athymic nude mice.

Authors:  Lars Steinstraesser; Frank Jacobsen; Cornelius Schubert; Kai Gevers; Ingo Stricker; Hans-Ulrich Steinau; Sammy Al-Benna
Journal:  Hum Cell       Date:  2010-05       Impact factor: 4.174

6.  Radio-sensitization of the murine osteosarcoma cell line LM8 with parthenolide, a natural inhibitor of NF-κB.

Authors:  Kenjiro Sugiyasu; Katsuhiko Nanno; Noriyuki Tamai; Nobuyuki Hashimoto; Yuki Kishida; Hideki Yoshikawa; Akira Myoui
Journal:  Oncol Lett       Date:  2011-03-21       Impact factor: 2.967

Review 7.  Ex vivo culture of human prostate tissue and drug development.

Authors:  Margaret M Centenera; Ganesh V Raj; Karen E Knudsen; Wayne D Tilley; Lisa M Butler
Journal:  Nat Rev Urol       Date:  2013-06-11       Impact factor: 14.432

8.  Sarcoma in 2016: Evolving biological understanding and treatment of sarcomas.

Authors:  Jean-Yves Blay; Isabelle Ray-Coquard
Journal:  Nat Rev Clin Oncol       Date:  2016-12-13       Impact factor: 66.675

Review 9.  Systemic treatment of soft-tissue sarcoma-gold standard and novel therapies.

Authors:  Mark Linch; Aisha B Miah; Khin Thway; Ian R Judson; Charlotte Benson
Journal:  Nat Rev Clin Oncol       Date:  2014-03-18       Impact factor: 66.675

10.  Myxofibrosarcoma primary cultures: molecular and pharmacological profile.

Authors:  Alessandro De Vita; Federica Recine; Laura Mercatali; Giacomo Miserocchi; Chiara Liverani; Chiara Spadazzi; Roberto Casadei; Alberto Bongiovanni; Federica Pieri; Nada Riva; Dino Amadori; Toni Ibrahim
Journal:  Ther Adv Med Oncol       Date:  2017-10-28       Impact factor: 8.168

View more
  8 in total

Review 1.  Precision Medicine in Head and Neck Cancers: Genomic and Preclinical Approaches.

Authors:  Giacomo Miserocchi; Chiara Spadazzi; Sebastiano Calpona; Francesco De Rosa; Alice Usai; Alessandro De Vita; Chiara Liverani; Claudia Cocchi; Silvia Vanni; Chiara Calabrese; Massimo Bassi; Giovanni De Luca; Giuseppe Meccariello; Toni Ibrahim; Marco Schiavone; Laura Mercatali
Journal:  J Pers Med       Date:  2022-05-24

2.  The potential role of the extracellular matrix in the activity of trabectedin in UPS and L-sarcoma: evidences from a patient-derived primary culture case series in tridimensional and zebrafish models.

Authors:  Laura Mercatali; Toni Ibrahim; Alessandro De Vita; Federica Recine; Giacomo Miserocchi; Federica Pieri; Chiara Spadazzi; Claudia Cocchi; Silvia Vanni; Chiara Liverani; Anna Farnedi; Francesco Fabbri; Valentina Fausti; Roberto Casadei; Francesca Brandolini; Giorgio Ercolani; Davide Cavaliere; Alberto Bongiovanni; Nada Riva; Lorena Gurrieri; Giandomenico Di Menna; Sebastiano Calpona; Silvia Angela Debonis
Journal:  J Exp Clin Cancer Res       Date:  2021-05-11

3.  Secondary Leiomyosarcoma of the Lower Limb Following Uterine Smooth Muscle Tumor of Uncertain Malignant Potential.

Authors:  Jose María García-Sánchez; Mónica Bauza; Alberto Pérez-García; Empar Mayordomo Aranda; Alejandro Ruiz Valls
Journal:  Clin Med Insights Case Rep       Date:  2019-06-24

Review 4.  Current Approaches for Personalized Therapy of Soft Tissue Sarcomas.

Authors:  Kirill I Kirsanov; Ekaterina A Lesovaya; Timur I Fetisov; Beniamin Yu Bokhyan; Gennady A Belitsky; Marianna G Yakubovskaya
Journal:  Sarcoma       Date:  2020-03-31

5.  Case Report: Adult NTRK-Rearranged Spindle Cell Neoplasm: Early Tumor Shrinkage in a Case With Bone and Visceral Metastases Treated With Targeted Therapy.

Authors:  Federica Recine; Alessandro De Vita; Valentina Fausti; Federica Pieri; Alberto Bongiovanni; Eugenia Franchini; Roberto Casadei; Maria Cristina Falasconi; Devil Oboldi; Federica Matteucci; Maria Caterina Pallotti; Laura Mercatali; Nada Riva; Lorena Gurrieri; Silvia Vanni; Chiara Liverani; Giacomo Miserocchi; Chiara Spadazzi; Claudia Cocchi; Toni Ibrahim
Journal:  Front Oncol       Date:  2022-01-07       Impact factor: 6.244

6.  Deciphering the Genomic Landscape and Pharmacological Profile of Uncommon Entities of Adult Rhabdomyosarcomas.

Authors:  Alessandro De Vita; Silvia Vanni; Valentina Fausti; Claudia Cocchi; Federica Recine; Giacomo Miserocchi; Chiara Liverani; Chiara Spadazzi; Massimo Bassi; Manlio Gessaroli; Angelo Campobassi; Giovanni De Luca; Federica Pieri; Anna Farnedi; Eugenia Franchini; Anna Ferrari; Chiara Domizio; Enrico Cavagna; Lorena Gurrieri; Alberto Bongiovanni; Nada Riva; Sebastiano Calpona; Giandomenico Di Menna; Silvia Angela Debonis; Toni Ibrahim; Laura Mercatali
Journal:  Int J Mol Sci       Date:  2021-10-26       Impact factor: 5.923

7.  A Rationale for the Activity of Bone Target Therapy and Tyrosine Kinase Inhibitor Combination in Giant Cell Tumor of Bone and Desmoplastic Fibroma: Translational Evidences.

Authors:  Alessandro De Vita; Silvia Vanni; Giacomo Miserocchi; Valentina Fausti; Federica Pieri; Chiara Spadazzi; Claudia Cocchi; Chiara Liverani; Chiara Calabrese; Roberto Casadei; Federica Recine; Lorena Gurrieri; Alberto Bongiovanni; Toni Ibrahim; Laura Mercatali
Journal:  Biomedicines       Date:  2022-02-03

8.  Characterization and Drug Sensitivity of a New High-Grade Myxofibrosarcoma Cell Line.

Authors:  Giacomo Miserocchi; Alessandro De Vita; Laura Mercatali; Federica Recine; Chiara Liverani; Chiara Spadazzi; Federica Pieri; Nada Riva; Alberto Bongiovanni; Roberto Casadei; Valentina Fausti; Toni Ibrahim
Journal:  Cells       Date:  2018-10-25       Impact factor: 6.600

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.